eigerbioadmin

Home»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 176 blog entries.
3 08, 2020

Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences

2020-08-03T13:34:43+00:00

Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences PALO ALTO, Calif., August 3, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August. BTIG Virtual Biotechnology Conference [...]

Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences2020-08-03T13:34:43+00:00
29 05, 2020

Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020

2020-05-29T20:24:18+00:00

Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020 PALO ALTO, Calif. – May 29, 2020  –  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support [...]

Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 20202020-05-29T20:24:18+00:00
26 05, 2020

Eiger to Present at Jefferies Virtual Healthcare Conference 2020

2020-05-26T21:20:28+00:00

Eiger to Present at Jefferies Virtual Healthcare Conference 2020 PALO ALTO, Calif. – May 26, 2020 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies Virtual Healthcare Conference on June 4, [...]

Eiger to Present at Jefferies Virtual Healthcare Conference 20202020-05-26T21:20:28+00:00
19 05, 2020

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

2020-05-19T21:14:10+00:00

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies PALO ALTO, Calif. May 19, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug [...]

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies2020-05-19T21:14:10+00:00
7 05, 2020

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-07T20:42:20+00:00

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif. May 7, 2020 — Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. “We achieved key milestones [...]

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update2020-05-07T20:42:20+00:00
30 04, 2020

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

2020-04-30T13:57:03+00:00

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda Six International, Investigator Sponsored Studies Initiating and Enrolling PALO ALTO, Calif. April 30, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients have been dosed in [...]

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda2020-04-30T13:57:03+00:00
27 04, 2020

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies

2020-04-27T13:57:56+00:00

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies Accelerated Assessment of MAA Previously Granted by EMA in March PALO ALTO, Calif. April 27, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that [...]

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies2020-04-27T13:57:56+00:00
3 04, 2020

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

2020-04-03T11:04:09+00:00

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating   PALO ALTO, Calif. April 1, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare [...]

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic2020-04-03T11:04:09+00:00
23 03, 2020

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

2020-03-23T17:54:46+00:00

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO,  Calif. March 23, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, [...]

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies2020-03-23T17:54:46+00:00
13 03, 2020

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

2020-03-13T15:27:43+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA Progeria NDA Submission Complete by End of March 2020 Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif., March 13, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update2020-03-13T15:27:43+00:00
Eiger BioPharmaceuticals © 2018 | All Rights Reserved
Toggle Sliding Bar Area
Go to Top